⌘+K

Pulse Explore Clubs Researchers Journals

Home Clubs Explore

July 28, 2023The Journal of Infectious DiseasesOpen Access

Drug Resistance Assessed in a Phase 3 Clinical Trial of Maribavir Therapy for Refractory or Resistant Cytomegalovirus Infection in Transplant Recipients

View Full Paper

Ask AI

Bookmark

Share

No abstract yet

We only have this paper's title and publication details.

Read it at the source→

Abstract

Nct02931539.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Chou et al. (2023) studied this question.

synapsesocial.com/papers/69de9dba6bae133e7de94591 https://doi.org/10.1093/infdis/jiad293

View Full Paper

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1International Consensus Guidelines on the Management of Cytomegalovirus in Solid Organ TransplantationRisk Assessment · 2010 · 966 citations
2Diverse Cytomegalovirus UL27 Mutations Adapt to Loss of Viral UL97 Kinase Activity under MaribavirOriginal Research · 2008 · 61 citations
3Accelerated Evolution of Maribavir Resistance in a Cytomegalovirus Exonuclease Domain II MutantOriginal Research · 2007 · 88 citations
4The Third International Consensus Guidelines on the Management of Cytomegalovirus in Solid-organ TransplantationOriginal Research · 2018 · 1,168 citations
5Novel UL97 drug resistance mutations identified at baseline in a clinical trial of maribavir for resistant or refractory cytomegalovirus infectionEarly-Phase Clinical Trial · 2019 · 42 citations